Metlifecare Limited develops, owns, and operates retirement villages in New Zealand.
Reasonable growth potential with imperfect balance sheet.
Share Price & News
How has Metlifecare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MET's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MET matched the NZ Healthcare industry which returned 32.7% over the past year.
Return vs Market: MET exceeded the NZ Market which returned 21.9% over the past year.
Price Volatility Vs. Market
How volatile is Metlifecare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StShould You Be Concerned About Metlifecare Limited's (NZSE:MET) ROE?
2 months ago | Simply Wall StHere’s why Metlifecare Limited’s (NZSE:MET) Returns On Capital Matters So Much
2 months ago | Simply Wall StCould Metlifecare Limited's (NZSE:MET) Investor Composition Influence The Stock Price?
Is Metlifecare undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MET (NZ$6.93) is trading above our estimate of fair value (NZ$3)
Significantly Below Fair Value: MET is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MET is poor value based on its PE Ratio (37.6x) compared to the Healthcare industry average (24.4x).
PE vs Market: MET is poor value based on its PE Ratio (37.6x) compared to the NZ market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: MET is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: MET is good value based on its PB Ratio (1x) compared to the NZ Healthcare industry average (1.2x).
How is Metlifecare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MET's forecast earnings growth (26.3% per year) is above the savings rate (1.3%).
Earnings vs Market: MET's earnings (26.3% per year) are forecast to grow faster than the NZ market (6.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MET's revenue (6.9% per year) is forecast to grow faster than the NZ market (5.1% per year).
High Growth Revenue: MET's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MET's Return on Equity is forecast to be low in 3 years time (7%).
How has Metlifecare performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MET has a large one-off gain of NZ$40.2M impacting its June 30 2019 financial results.
Growing Profit Margin: MET's current net profit margins (31.6%) are lower than last year .
Past Earnings Growth Analysis
Earnings Trend: MET's earnings have declined by -2.3% per year over the past 5 years.
Accelerating Growth: MET's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MET had negative earnings growth (-68%) over the past year, making it difficult to compare to the Healthcare industry average (-2.9%).
Return on Equity
High ROE: MET's Return on Equity (2.6%) is considered low.
Return on Assets
Return on Capital Employed
How is Metlifecare's financial position?
Financial Position Analysis
Short Term Liabilities: MET's short term assets (NZ$26.9M) do not cover its short term liabilities (NZ$166.6M).
Long Term Liabilities: MET's short term assets (NZ$26.9M) do not cover its long term liabilities (NZ$1.9B).
Debt to Equity History and Analysis
Debt Level: MET's debt to equity ratio (18.8%) is considered satisfactory.
Reducing Debt: MET's debt to equity ratio has increased from 5.3% to 18.8% over the past 5 years.
Debt Coverage: MET's debt is well covered by operating cash flow (43%).
Interest Coverage: MET's interest payments on its debt are not well covered by EBIT (1x coverage).
Inventory Level: MET has a low level of unsold assets or inventory.
Debt Coverage by Assets: MET's debt is not covered by short term assets (assets are 0.1x debt).
What is Metlifecare's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MET's dividend (1.59%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.87%).
High Dividend: MET's dividend (1.59%) is low compared to the top 25% of dividend payers in the NZ market (5.53%).
Stability and Growth of Payments
Stable Dividend: MET is not paying a notable dividend for the NZ market, therefore no need to check if payments are stable.
Growing Dividend: MET is not paying a notable dividend for the NZ market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MET is not paying a notable dividend for the NZ market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MET's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Glen Sowry 0
Mr. Glen R. Sowry, INSEAD AMP, has been the Chief Executive Officer of Metlifecare Limited since April 2016. Mr. Sowry served as the Chief Executive Officer of Housing New Zealand Corporation since January ...
CEO Compensation Analysis
Compensation vs Market: Glen's total compensation ($USD690.75K) is about average for companies of similar size in the NZ market ($USD655.47K).
Compensation vs Earnings: Glen's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||3.8yrs||NZ$1.08m||0.0047% NZ$69.3k|
|Chief Financial Officer||2.4yrs||no data||no data|
|General Manager of Operations||5.1yrs||no data||no data|
|General Manager of Marketing||3.1yrs||no data||no data|
|General Manager of Sales||0.6yrs||no data||no data|
Experienced Management: MET's management team is considered experienced (3.1 years average tenure).
|Independent Director||2.5yrs||NZ$92.50k||0.0070% NZ$104.0k|
|Independent Director||7.5yrs||NZ$97.50k||0.0065% NZ$96.3k|
|Independent Chairman of the Board||5.4yrs||NZ$165.00k||0.12% NZ$1.8m|
|Independent Director||2.5yrs||NZ$87.50k||0.0033% NZ$48.5k|
|Independent Director||7.5yrs||NZ$95.00k||0.014% NZ$201.3k|
|Non Executive Director||6.7yrs||NZ$87.50k||0.0019% NZ$27.7k|
|Non-Independent & Non-Executive Director||6.2yrs||NZ$92.50k||no data|
Experienced Board: MET's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Metlifecare Limited's company bio, employee growth, exchange listings and data sources
- Name: Metlifecare Limited
- Ticker: MET
- Exchange: NZSE
- Founded: 1984
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: NZ$1.475b
- Shares outstanding: 212.78m
- Website: https://www.metlifecare.co.nz
- Metlifecare Limited
- 20 Kent Street
- Level 4
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MET||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Jan 1995|
Metlifecare Limited develops, owns, and operates retirement villages in New Zealand. The company offers independent living homes, care apartments, and care beds and suites. It owns and operates 25 villages. The company was founded in 1984 and is based in Auckland, New Zealand.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 10:32|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.